Search

Displaying results 1721 - 1730 of 10000 in total
  1. Drug

    Dabrafenib

    go.drugbank.com/drugs/DB08912
    ApprovedInvestigational

    [L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955] … It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation.[L41955] It was also used for metastatic non-small cell lung cancer with the same mutation.

  2. Drug

    Flosequinan

    go.drugbank.com/drugs/DB13228
    ApprovedWithdrawn

    Flosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due to increased mortality in chronic heart failure patients, found in drug trials.[A174979,L43942]

    Categories: Vasodilators Used in Cardiac Diseases
  3. Drug

    Hydroflumethiazide

    go.drugbank.com/drugs/DB00774
    ApprovedWithdrawn

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)

  4. Drug

    Zolmitriptan

    go.drugbank.com/drugs/DB00315
    ApprovedInvestigational

    [A193791] Triptans can be administered alone or in combination with an NSAID like [naproxen], and represent the current "gold standard" for acute migraine treatment. … It is currently available in both tablet and nasal spray forms.[L12978]

  5. Drug

    Cenegermin

    go.drugbank.com/drugs/DB13926
    ApprovedInvestigational

    [L4563] In particular, cenegermin was granted Priority Review designation, under which the FDA’s goal is to take action on an application within six months of application filing where the agency determines … [L4563] While the prevalence of neurotrophic keratitis is low, the impact of this serious condition and its associated sequelae on an individual patient can be debilitating.

  6. Drug

    Vonoprazan

    go.drugbank.com/drugs/DB11739
    ApprovedInvestigational

    [A253707] In February 2015, vonoprazan was first marketed in Japan for the treatment of acid-related disorders and as an adjunct to _Helicobacter pylori_ (_H. pylori_) eradication. … [A253702] In May 2022, the FDA approved the use of vonoprazan in a co-packaged product containing amoxicillin and clarithromycin for the treatment of _H. pylori_ infection.

    Synonyms: 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine
  7. Drug

    Thonzonium

    go.drugbank.com/drugs/DB09552
    Approved

    It is also reported that thonzonium also confers an antifungal property and antiresorptive effect on bone. … It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication.

  8. Drug

    Elinzanetant

    go.drugbank.com/drugs/DB18968
    ApprovedInvestigational

    in thermo-regulation. … [L53798] By blocking receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons, which are hyperactivated due to estrogen decline in menopause, elinzanetant modulates neuronal activity involved

    Synonyms: 2-(3,5-bis(trifluoromethyl)phenyl)-n-(4-(4-fluoro-2-methylphenyl)-6-((7s,9as)-7-(hydroxymethyl)hexahydropyrazino(2,1-c)(1,4)oxazin-8(1h)-yl)-3-pyridinyl)-n,2-dimethylpropanamide, Benzamide, 3-(5-methyl-2-tbenzeneacetamide, n-(4-(4-fluoro-2-methylphenyl)-6-((7s,9as)-hexahydro-7-(hydroxymethyl)pyrazino(2,1-c)(1,4)oxazin-8(1h)-yl)-3-pyridinyl)-n,.alpha.,.alpha.
  9. Drug

    gamma-Hydroxybutyric acid

    go.drugbank.com/drugs/DB01440
    ApprovedIllicitInvestigational

    It is currently regulated in the US and sold by Jazz Pharmaceuticals under the name Xyrem. However, it is important to note that GHB is a designated Orphan drug (in 1985). … GHB is a naturally occurring substance found in the central nervous system, wine, beef, small citrus fruits and almost all other living creatures in small amounts.

    Synonyms: oxy-n-butyric acid
  10. Drug

    Esketamine

    go.drugbank.com/drugs/DB11823
    ApprovedInvestigational

    The FDA approved ketamine (Ketalar) in 1970. … [L5593] Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications

    Categories: Non-Competitive N-Methyl D-Aspartate (NMDA) Receptor AntagonistsProducts: Eskelan 25 mg/ml-Injektions-/Infusionslösung in Ampullen, Eskelan 25 mg/ml-Injektionslösung in Durchstechflaschen